Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Pain. 2018 Aug;159(8):1652–1663. doi: 10.1097/j.pain.0000000000001253

Figure 2: SCD cold behavioral sensitivity is mediated by CCR2 signaling.

Figure 2:

Cold sensitivy was assessed in Berk SS and B6;129 controls using the plantar dry ice assay. (A.) Both transgenic strains exhibited marked cold sensitivty (two-way ANOVA significant main effect of genotype F2,24 = 54.37, p<0.0001; Bonferroni multiple comparison test B6;129 vehicle vs. Townes AS vehicle ***p=0.0002, B6;129 vehicle vs. Berk SS vehicle ****p<0.0001; n=5–6). Subcutaneous neck administration of the CCR2 antagonist RS 504393 (3 mg/kg) increased withdrawal latencies, most significantly in Townes AS and Berk SS mice (two-way ANOVA significant main effect of RS 504393 F1,24 = 114.7, p<0.0001 and genotype x RS 504393 interaction F2,24=6.626, p=0.0051; Bonferroni multiple comparison test B6;129 vehicle vs. B6;129 RS 504393 ##p=0.0050, Townes AS vehicle vs. Townes AS RS 504393 #### p<0.0001, Berk SS vehicle vs. Berk SS RS 504393 #### p<0.0001, B6;129 RS 504393 vs. Berk SS RS 504393 &&&&p<0.0001). (B.) Subcutaneous administration of the CCR4 antagonist C 021 (3 mg/kg) did not alleviate cold hypersensitivity observed in Townes AS and Berk SS mice (two-way ANOVA significant main effect of genotype F2,27=139.6, p<0.0001; Bonferroni multiple comparison test B6;129 vehicle vs. Townes AS vehicle *p=0.0119, B6;129 vehicle vs. Berk SS vehicle ****p<0.0001, B6;129 C 021 vs. Townes AS C 021 &&p=0.0039, B6;129 C 021 vs. Berk SS C 021 &&&&p<0.0001; n=5–6). (C.) Similarly, i.p. administartion of the TRPV1 antagonist A-425619 (34.5 mg/kg) did not alleviate SCD-related cold hypersensitivity exhibited by Townes AS and Berk SS mice (two-way ANOVA significant main effect of genotype F2,28=165.0, p<0.0001; Bonferroni multiple comparison test B6;129 vehicle vs. Townes AS vehicle ****p<0.0001, B6;129 vehicle vs. Berk SS vehicle ****p<0.0001, B6;129 A-425619 vs. Townes AS A-425619 &&&&p<0.0001, B6;129 A-425619 vs. Berk SS A-425619 &&&&p<0.0001; n=5–8). (D.) Intraplantar administration of the TRPA1 antagonist HC-030031 (100 μg/ 30 μL) also had no effect on Townes AS or Berk SS cold hypersensitivity (two-way ANOVA significant main effect of genotype F2,32=23.63, p<0.0001; Bonferroni multiple comparison test B6;129 vehicle vs. Berk SS vehicle **p=0.0038, B6;129 HC-030031 vs. Townes AS HC-030031 &&p=0.019, B6;129 HC-030031 vs. Berk SS HC-030031 &&&p=0.0002; n=5–9).